Summary The expression of the gp100 antigen is generally thought to be confined to cells of the melanocytic lineage, which makes the protein a suitable melanoma-specific marker. Strikingly, after screening a panel of normal tissues, tumour samples and cell lines of nonmelanocytic origin, we found transcripts encoding gplOO in virtually every tissue and cell line tested. In contrast, tyrosinase and MART-1/MelanA transcripts were detected only in cells of the melanocytic lineage. However, no gpl 00 protein could be detected by either Western blotting or cytotoxicity assays. Therefore, at the protein level, gp100 remains exclusive for cells of melanocytic origin despite its transcription in many cell types. The major implication of this finding is that screening of patient material for gp100 expression should preferrably be performed by antibody staining. Reverse transcriptase polymerase chain reaction (RT-PCR) can be employed, provided that it is performed in a tightly controlled, semiquantitative setting.
The molecular cloning of tumour-associated antigens has provided new tools for the immunotherapy of cancer (reviewed in Van den Eynde and Brichard, 1995) . Now it has become feasible to immunize cancer patients against these antigens to stimulate specifically a cellular anti-tumour response (Marchand et al, 1995) . To select patients eligible for immunotherapeutic protocols, the antigenic profiles of the patients' tumours must be characterized. This is usually achieved by reverse transcriptase polymerase chain reaction (RT-PCR) using RNA obtained from tumour samples when available. An alternative source of tumour cells is whole blood, which often contains numerous circulating residual tumour cells (Brossart et al, 1995; Hoon et al, 1995) . A suitable antigen to target in melanoma is gplOO because it is thought to be specific for cells of melanocytic lineage and it is adequately expressed in melanoma cells. Expression in non-melanocytic cells, at least as measured by antibody reactivity (Vennegoor et al, 1988) or Northern analysis (Kawakami et al, 1994) , is virtually absent. In a routine RT-PCR screening of a number of human tumour samples and normal tissues, we noticed to our surprise that gplOO transcripts were present in almost all materials tested, whereas the protein was not detectable.
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MATERIALS AND METHODS Tumour cell lines, samples and normal tissues
The renal cell carcinoma cell lines (RCC) LE-9104-RCC, LE-921 l-RCC and LE-9415-RCC and the melanoma cell line Mel 603 were established in our laboratory. The RCC cell line SK-RC-7 was kindly provided by Dr E Oosterwijk (Department of Urology, Nijmegen University, The Netherlands). The RCC cell lines MZ-1851-RCC and Camejo and melanoma cell lines MZ-2-mel and MZ-7.4-mel were generously provided by Dr B Seliger (J Gutenberg University, Mainz, Germany). The breast carcinoma cell lines (BRCA) MCF-7 and SK-BR-3 were a gift from Dr R Kuypers (Department of Pathology, Leiden University, The Netherlands). The ovarian carcinoma cell lines (OVCA) COV 434 and COV 413A were established in our laboratory (Van den Berg-Bakker et al, 1993) . The melanoma cell line Mel 624 and TIL 1200 lymphocytes were kindly provided by Dr Y Kawakami (NCI, NIH, Bethesda, MD, USA). LE-8915-EBV and PS-EBV are EBV-transformed B-cell lines established in our laboratory. BLM is a melanoma cell line (Bakker et al, 1994) . Normal tissues were obtained after death from a woman without cancer. Fresh retina was kindly provided by Dr M Jager (Department of Ophthalmology, Leiden University, The Netherlands).
RNA isolation and cDNA synthesis Total RNA was isolated by guanidine-thiocyanate (HSCN) extraction as described by Chomczynski and Sacchi (1987) or using RNAzolB (Tel-Test, Friendswood, TX, USA). Before cDNA gp100 expression in non-melanocytic cells 1563 (2) (-1) The integrity of the cDNA was assessed by PCR for ,-actin.
Cell lines PCR analysis PCR was performed with 2.5 pl of the cDNA in 1 x PCR buffer, 2 mm magnesium chloride, dNTP (10 mm each), 10 pmol of both primers, 0.05% WI, 0.5 U of Taq (Gibco BRL) in a volume of 25 ,l. The PCR primers and programmes used were: 3-actin, sense 5'-GGCATCGTGATGGACTCCG-3', antisense 5'-GCTG-GAAGGTGGACAGCGA-3', 5 min at 94°C (1 min at 94°C, 2 min at 680C, 2 min at 72°C), 30x, 15 min at 72°C (Guilloux et al, 1996) . GplOO, sense 5'-TATFGAAAGTGCCGAGATCC-3', antisense 5'-TGCAAGGACCACAGCCATC-3', 5 min at 940C
(1 min at 94°C, 1 min at 60°C, 1 min 72°C), 35x, 15 min at 72°C . Tyrosinase, sense 5'-TTGGCAGATTGTCT-GTAGCC-3', antisense 5'-AGGCATTGTGCATGCTGCTF-3', 5 min at 94°C (1 min at 94°C, 1 min at 60°C, 1 min at 72°C), 30 x, 15 min at 72°C (Smith et al, 1991) . MART-l/MelanA, sense 5'-CTGACCCTACAAGATGCCAAGAG-3', antisense 5'-ATCA-TGCATTGCAACATTTATTGATGGAG-3', 5 min at 94°C (1 min at 940C, 2 min at 630C, 2 min at 720C) 35 x, 15 min at 72°C. RAGE-1, sense 5'-GTGTCTCCTTCGTCTCTACTA-3', antisense 5'-GAGGTATTCCTGATCCTG-3', 5 min at 94°C (1 min at 94°C, 2 min at 560C, 3 min at 720C), 33 x, 15 min at 72°C (Gaugler et al, 1996 
Cytotoxicity assay
Cytotoxicity towards the cell lines was performed as described previously (Bakker et al, 1995) . The target cells were pretreated with 50 U ml-' y-IFN for 48 h before testing. Figure 1 , the gplOO-specific PCR products of a representative selection of these different cell lines are shown. In contrast, no tyrosinase or MART-l/MelanA transcripts were detected, except in cells of melanocytic origin. The RAGE-I cDNA, which was recently cloned from a renal cell carcinoma cell line, was detected in RCC cell line MZ-185 1-RCC and in fresh retina (Figure 1 ) (Gaugler et al, 1996) . (Kawakami et al, 1994) .
No gplOO protein was detected by Western blotting
Next, we analysed whether gplOO protein could be detected by Western blotting (Figure 2 ). In Mel 603 and MZ-7.4-mel, positive for gplOO by RT-PCR, gplOO protein was clearly detected by the AZN-LAM antiserum. In the RCC cell lines Camejo, LE-9104-RCC, SK-RC-7, LE-921 1-RCC, which were all positive using RT-PCR (not shown), no gplOO protein was detected. COS-7 cells were negative for gplOO by RT-PCR and Western blotting.
Cytotoxicity
Although we did not detect gplOO protein by Western blotting in the RCC cell lines that were all found to be positive by RT-PCR, antigenic processing of a very small amount of gplOO protein might still lead to MHC class I-mediated presentation of gplOO peptides. As CTL recognition requires only a few antigenic complexes on the cell surface, we tested a number of HLA-A*0201-positive, gplOO-positive RCC cell lines for lysis using the gplOO-specific TIL 1200 cytotoxic T-cell line (Bakker et al, 1995) . None of the HLA-A*0201-positive, gplOO-positive RCC cell lines was lysed, whereas the control melanoma cell line Mel 624 was readily lysed, suggesting that the level of expression of gplOO occurs at an immunologically irrelevant level (Table 1) .
gplOO expression in non-melanocytic cells 1565
Low expression of gplOO transcripts in RCC Although gplOO transcripts can be detected by RT-PCR in various tissues, the gplOO protein is apparently not detected by cytotoxic T cells. To investigate whether this is caused by low transcription levels, we used semiquantitative PCR to compare the levels of expression in the various cell lines with that of Mel 624.
Radioactive PCR for either P-actin or gplOO was perforihed using 21 and 25 cycles of amplification respectively, and the products were run on acrylamide gels and quantified by phosphor-imaging. The f-actin signals in Mel 624 and MCF-7 were similar, whereas the signal in JY cells was higher at the different cDNA dilutions (Figure 3) . The gplOO signal, however, could readily be detected in the melanoma cell line even after a 1: 104-fold dilution, but 1:5 dilutions of the cDNA of MCF-7 and JY cells yielded barely detectable gplOO-specific PCR products. In contrast to other antigens that were identified by expression cloning with specific T cells, the gplOO antigen was first identified by antibody reactivity (Vennegoor et al, 1988; Adema et al, 1994) . Staining with MAbs NKI/beteb or HMB-45 could only be detected in cells of the melanocytic lineage. After cloning of the gplOO cDNA, the tissue-specific distribution was confirmed by Northern analysis (Kawakami et al, 1994) . The gplOO protein is a transmembrane protein that localizes primarily on the inside of premelanosomal vesicles. The function of the protein is unknown at present. Using RT-PCR, we show that there is a low level of transcription of gplOO in virtually every cell type. Similar findings were published by Chelly et al (1989) , who showed that various other tissue-specific genes could be detected by RT-PCR in various tissues. They suggested that modification of the chromatin structure during DNA replication allowed ubiquitous transcription factors to bind to their cognate DNA elements, resulting in a low level of transcription. The level of gplOO protein expressed, however, is undetectable in these cell types. From these findings we conclude that gplOO can still be considered as a marker for cells of melanocytic lineage.
DISCUSSION
Screening of cancer patients for the presence of tumour antigens as eligibility criteria for immunotherapeutical protocols is already performed in the case of MAGE-3 (Marchand et al, 1995) . Moreover, tyrosinase-specific RT-PCR is used for the detection of micrometastases in melanoma patients (Proebstle et al, 1996; Rankin, 1996) . To obtain clinically relevant information, screening for gplOO expression within tumour material should be performed by antibody staining. Our experiments suggest that lysis by gplOOspecific T cells only correlates with expression of gplOO at the protein level but not with RT-PCR expression data. Alternatively, a threshold value of gplOO expression, at which CTL recognition still occurs, should be determined by semiquantitative PCR. A similar situation probably exists for the melanoma-specific antigen N-acetylglucosaminyl-transferase V, which could be detected by RT-PCR but not by CTL, when the antigen was expressed at levels lower than 8% of the reference (Guilloux et al, 1996) . Our data indicate that a tightly controlled, semiquantitative PCR protocol should be developed in which gplOO is only detected when expressed at biologically revelant levels. Rankin EM (1996) 
